Dolutegravir Resistance: What the DTG RESIST Study Means for the SHCS and People with HIV
The DTG RESIST study examined dolutegravir (DTG) resistance in people with HIV who were taking DTG-based treatment but still had a high viral load. DTG is one of the most important HIV drugs worldwide and is usually highly effective. The study therefore asked how often resistance occurs among people whose treatment is no longer fully suppressing HIV in routine care in sub-Saharan Africa.
The study included 488 adults and adolescents from 16 sites in seven African countries. Of 227 participants who could be tested for integrase resistance, 59 (26%) had major resistance mutations, and 49 (21.6%), about one in five, had predicted high-level resistance to DTG. Most people with resistance had several resistance mutations rather than only one.
Importantly, resistance was found only in people who had already received HIV treatment before starting DTG. None of the evaluable participants who began DTG as their first HIV treatment had major DTG-resistance mutations. The study therefore does not suggest that DTG commonly fails in people starting modern HIV treatment. The main concern is persistent viral replication in treatment-experienced people.
DTG resistance also often occurred together with resistance to other HIV drugs. Almost all participants with major DTG resistance also had the M184V mutation, which affects lamivudine and emtricitabine, and many had resistance linked to older treatment regimens. About one third had intermediate- or high-level resistance to tenofovir. By contrast, protease inhibitor resistance was uncommon, and all participants with such resistance remained predicted to be susceptible to darunavir.
What does this mean for the SHCS?
These results cannot simply be translated into a 20% DTG-resistance rate in the Swiss HIV Cohort Study (SHCS). The authors point out that high-level DTG resistance has been much rarer in European and North American cohorts. Differences may reflect more frequent viral-load monitoring, earlier resistance testing and treatment changes, different treatment histories, and possibly different HIV subtypes.
The study is nevertheless highly relevant to the SHCS. It reinforces the importance of responding quickly to persistent viraemia on a DTG-containing regimen. In treatment-experienced patients with confirmed viraemia, clinicians should review adherence, drug interactions, previous treatment and resistance history, and consider genotypic resistance testing early.
For the SHCS as a research cohort, the findings also raise useful questions about who develops DTG resistance, how long viraemia precedes resistance, and whether treatment history or HIV subtype affects risk.
What does this mean for people with HIV?
For most people with HIV, the message remains reassuring. DTG is still a highly effective drug, and this study does not show that resistance is common when the virus remains suppressed. The concern is mainly for people whose virus continues to replicate despite DTG-based treatment.
The practical message is that regular viral-load monitoring matters. A detectable viral load does not automatically mean DTG resistance, because missed doses, drug interactions or other factors may also play a role. However, if viraemia persists, resistance testing becomes important so that treatment can be adjusted before additional resistance develops.
In short: DTG remains an excellent HIV treatment, but persistent viraemia on DTG deserves prompt investigation. The study supports close viral-load monitoring, timely resistance testing and early treatment optimization for people with HIV.